The Company intends to use the net proceeds for the commercialization of its diagnostic called CyPath Lung, a non-invasive test for the early detection of lung cancer that has completed a clinical trial showing 92% sensitivity and 87% specificity in detecting lung cancer in individuals at high risk who have lung nodules less than 2 centimeters. 20220728US bioAffinity Technologies, Inc.(S-1) . This press release contains forward-looking statements, including statements regarding the anticipated use of proceeds from the Companys offering of its units. SAN ANTONIO, November 14, 2022--bioAffinity Technologies reports third quarter 2022 financial results and provides business update, including completion of $15.6 million IPO. Through our subsidiary, OncoSelect Therapeutics, we are advancing our discoveries to create broad-spectrum cancer therapeutics. San Antonio, TX September 6, 2022 bioAffinity Technologies, Inc. (bioAffinity or the Company) (NASDAQ: BIAF, BIAFW), a cancer diagnostics company that develops noninvasive, early-stage diagnostics to detect cancer and diseases of the lung, and is researching targeted therapies to treat cancer, announced today it has completed its previously announced initial public offering (IPO) of 1,282,600 units, each consisting of one share of common stock, one tradeable warrant to purchase one share of common stock at an exercise price of $7.35 per share, and one non-tradeable warrant to purchase one share of common stock at an exercise price of $7.656 per share, for aggregate gross proceeds of approximately $7.8 million, prior to deducting underwriting discounts, commissions, and other offering expenses. Bauta, J.R. Sanchez, T.D. Each unit, which has no stand-alone rights and will not be certificated or issued as a stand-alone security, consists of one share of common stock, one tradeable warrant to purchase one share of common stock at an exercise price of $7.35 per share, and one non-tradeable warrant to purchase one share of common stock at an exercise price of $7.656 per share. The Company is focused on leveraging its wide platform technologies to generate tailored therapies to treat cancer through its wholly-owned subsidiary, OncoSelect Therapeutics, LLC. Addressing a critical need to find cancer early and treat cancer specifically bioAffinity Technologies develops tests and therapies to detect and treat cancer at the cellular level. The Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws. (2022) Sputum analysis by flow cytometry; an effective platform to analyze the lung environment. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. Elzi, P. Fatland, B. Karia, M. Iza, A Pertsemlidis, V.I. The Company intends to use the proceeds from the offering to expand . We are actively working to expand our core porphyrin platform technology to create targeted diagnostics and therapeutics in the fight against cancer. In researching porphyrins selectivity for cancer, we discovered novel therapies that kill cancer cells without harm to normal cells in vitro. In individuals at high risk for lung cancer with nodules less than 20 mm, (n=132). The shares of common stock and the tradable warrants may be transferred separately immediately upon issuance. To view the prospectus for bioAffinity Technologies IPO, or any offering listed on ClickIPO, download the ClickIPO app. Because the company offered units with warrants attached, bioAffinity Technologies will be excluded from Renaissance Capital's 2022 IPO stats. Under the new terms, the IPO's estimated proceeds are $7. bioAffinity Technologies addresses the urgent need for noninvasive, early-stage cancer diagnosis and targeted cancer treatment. Reveles, V.I. Addressing a critical need to find cancer early and treat cancer specifically bioAffinity Technologies develops tests and therapies to detect and treat cancer at the cellular level. Rebel, Meso-tetra (4-carboxyphenyl) porphyrin (TCPP) is incorporated into cancer cells by the CD320 receptor and clathrin-mediated endocytosis, American Society of Cell Biology (ASCB) Cell Bio 2020, Dec. 14, L.H. Copyright 2022 bioAffinity Technologies, Inc. Bederka L.H., Sanchez JR, Rebeles J, Araujo PR, Grayson MH, Lai S-C, et al. CyPath Lung is marketed as a Laboratory Developed Test by Precision Pathology Services. In addition, bioAffinity has granted the underwriters a 45-day option to purchase up to 192,390 shares of common stock, and/or 192,390 tradeable warrants, and/or 192,390 non-tradeable warrants, or any combination of additional shares of common stock and warrants representing, in the aggregate, up to 15% of the number of the units sold in this offering to cover over-allotments in this offering. It allows us to get to data on time now when we have tight deadlines. Forward-looking statements can be identified by words such as "believes," "expects," "estimates," "intends," "may," "plans," "will" and similar expressions, or the negative of these words. SAN ANTONIO-- ( BUSINESS WIRE )-- bioAffinity Technologies, Inc ., a cancer diagnostics company that develops noninvasive, early-stage diagnostics to detect cancer and diseases of the lung and is . This news release does not constitute an offer to sell or a solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Grayson, M.E. PLoS ONE, August 17, 2022, M.H. The issuer is planning to sell 1.5 million common shares at the price of $6.75 per share. Readers of this press release are cautioned not to place undue reliance on any forward-looking statements. bioAffinity Technologies, Inc., a cancer diagnostics company that develops noninvasive, early-stage diagnostics to detect cancer and diseases of the lung and is researching targeted therapies to treat cancer, announced today that its initial public offering of 1,282,600 units of securities has been priced at $6.125 per unit. L. Patriquin, D. Merrick, D. Hill, MD, R. Holcomb, V. Rebel, B. Karia, G. Bennett, T. Bauer II. Lemieux, J. Rebeles, S Lai, X.T. Research and optimization of the Companys platform technologies are conducted in its laboratories at The University of Texas at San Antonio. bioAffinity Technologies, Inc ., a cancer diagnostics company that develops noninvasive, early-stage diagnostics to detect cancer and diseases of the lung and is researching targeted therapies. The San Antonio, TX-based company now plans to raise $8 million by offering 1.3 million units at a price range of $6 to $6.25. bioAffinity Technologies addresses the urgent need for noninvasive, early-stage cancer diagnosis and targeted cancer treatment. Rebel Porphyrin uptake in lung cancer cells by dynamin-mediated endocytosis: a novel marker of dysregulated endocytosis in cancer, American Society of Cell Biology Annual Meeting, December 2015, L. Patriquin, D. Merrick, D. Hill, MD, R. Holcomb, V. Rebel, B. Karia, G. Bennett, T. Bauer II, Early Detection of Lung Cancer with Meso Tetra (4-Carboxyphenyl) Porphine (TCPP)-Labeled Sputum, Journal of Thoracic Oncology, September 2015. Pharvaris -16%. The CyPath Lung Flow Cytometry Test has been licensed by Precision Pathology Services for commercial sale as a Laboratory Developed Test (LDT). Reveles, V.I. bioAffinity Technologies Chief Executive Officer Maria Zannes said, We are pleased to have concluded the IPO process and are excited about opportunities that this funding and a presence on NASDAQ will bring. Companies main executive office is at 22211 West Interstate 10, Suite 1206, San Antonio, Texas 78257, and bioAffinity Technologies official phone number is (210 . mz@bioaffinitytech.com CyPath Lung is marketed as a Laboratory Developed Test by Precision Pathology Services. Compare models. This news release does not constitute an offer to sell or a solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. 505.400.9747, info@bioaffinitytech.com SAN ANTONIO, September 01, 2022--bioAffinity Technologies, Inc., a cancer diagnostics company that develops noninvasive, early-stage diagnostics to detect cancer and diseases of the lung and is researching targeted therapies to treat cancer, announced today that its initial public offering of 1,282,600 units of securities has been priced at $6.125 per unit. As of 12:30 EST, this security is trading at a volume of 159.0K shares, making up 8.6% of its average full-day volume over the . or a prospectus can be requested from G. Price at. We will continue with animal studies to advance our discoveries. BIAF intends to sell 1.5 million units of common stock and one warrant per share at a proposed midpoint price of $6.75 per share for gross proceeds of . bioAffinity Technologies, Inc. is a Delaware corporation addressing the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. SAN ANTONIO, September 01, 2022--bioAffinity Technologies, Inc., a cancer diagnostics company that develops noninvasive, early-stage diagnostics to detect cancer and diseases of the lung and is . Research and optimization of the Companys platform technologies are conducted in its laboratories at The University of Texas at San Antonio. L.H. I'm happy with it because it makes my job easier. This news release does not constitute an offer to sell or a solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Each warrant is immediately exercisable and will expire five years from the date of issuance. JERSEY CITY, N.J., Sept. 1, 2022 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that bio-Affinity. bioAffinity has the utmost confidence in the success of its business, The hard-working scientists and other professionals at . bioAffinity Technologies, Inc. (NASDAQ: BIAF; BIAFW) addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung, and targeted cancer treatment. bioAffinitys registration statement relating to these securities was declared effective as of August 29, 2022, by the U.S. Securities and Exchange Commission. The Companys first product called CyPath Lung is a noninvasive test that has shown high sensitivity and specificity for the detection of early-stage lung cancer. bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW) addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. bioAffinity Technologies, Inc. https://www.businesswire.com/news/home/20220901005311/en/. CyPath Lung is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Services. This press release contains forward-looking statements, including statements regarding the anticipated use of proceeds from the Companys offering of its units. Industry: Health Care. The number of securities and exercise prices reported in this Form 3 reflect the 1-for-7 reverse stock split of the common stock, par value $0.007 (the "Common Stock"), of bioAffinity Technologies, Inc. (the "Issuer"), which became effective with the State of Delaware on June 23, 2022 in connection with the Issuer's initial public offering (the "IPO"). CyPath Lung is marketed as a Laboratory Developed Test by Precision Pathology Services. mz@bioaffinitytech.com Today's IPO for bioAffinity Technologies, Inc. (BIAF) opened for trading at $8.40 after pricing 1,282,600 units of securities at $6.125 per unit. Reveles, V.I. Each warrant is immediately exercisable and will expire five years from the date of issuance. Electronic copies of the final prospectus relating to this offering may be obtained from WallachBeth Capital, LLC, Attention: Capital Markets, 185 Hudson Street, Jersey City, NJ 07311, by telephone at 646-998-7608, or by email at cap-mkts@wallachbeth.com. Things are so much faster now with IPRO. The offering is being made only by means of a prospectus. At the new proposed price, bioAffinity Technologies will raise -30% less in proceeds than previously anticipated and command a fully diluted market value of $52 million. The Company develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. Rebel. SAN ANTONIO- (BUSINESS WIRE)- #bioaffinity bioAffinity Technologies, Inc ., a cancer diagnostics company that develops noninvasive, early-stage diagnostics to detect cancer and diseases of the lung and is researching targeted therapies to treat cancer, announced today that its initial public offering of . SAN ANTONIO-- (BUSINESS WIRE)-- bioAffinity Technologies, Inc ., a cancer diagnostics company that develops noninvasive, early-stage diagnostics to detect cancer and diseases of the lung and is researching targeted therapies to treat cancer, announced today that its initial public offering of 1,282,600 units of securities has been priced at $6. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. Each unit, which has no stand-alone rights and will not be certificated or issued as a stand-alone security, consists of one share of common stock, one tradeable warrant to purchase one share of common stock at an exercise price of $7.35 per share, and one non-tradeable warrant to purchase one share of common stock at an exercise price of $7.656 per share. Rebel, D.J. bioAffinity Technologies Chief Executive Officer Maria Zannes said, "We are pleased to have concluded the IPO process and are excited about opportunities that this funding and a presence on NASDAQ will bring. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. To ensure the most secure and best overall experience on our website, we recommend the latest versions of. bioAffinity Technologies ( NASDAQ: BIAF) has filed to raise $18.8 million in an IPO of its common stock, according to an S-1 registration statement. WallachBeth Capital, LLC and Craft Capital Management, LLC are co-managers and co-book running managers for the offering. This press release contains forward-looking statements, including statements regarding the anticipated use of proceeds from the Companys offering of its units. Copies of the final prospectus may be obtained on the SECs website, http://www.sec.gov and by contacting WallachBeth Capital, LLC, Attention: Capital Markets, 185 Hudson Street, Jersey City, NJ 07311, by telephone at 646-998-7608, or by email at cap-mkts@wallachbeth.com. (2022). Grayson, X.T. D. J. Elzi, W. E. Bauta, J. R. Sanchez, S. Mogare, T. Das, P. Zannes-Fatland, V. I. The shares and the tradeable warrants will begin trading on September 1, 2022, on the Nasdaq Capital Market under the ticker symbols "BIAF" and "BIAFW," respectively. Our first product, CyPath Lung Flow Cytometry Test for Lung Cancer (CyPath Lung), has been licensed by Precision Pathology Services for commercial sale as a Laboratory Developed Test. Detecting cancer early with advanced flow cytometry. IPO . The tests automated analysis of the flow cytometry data detects cell populations that indicate cancer is present. Rebel, J. Rebeles, Quality Controlled Flow Cytometry for Lung Cancer Detection, JoVE, July 28, 2021, D. J. Elzi, W. E. Bauta, J. R. Sanchez, S. Mogare, T. Das, P. Zannes-Fatland, V. I. D. J. Elzi, W, E. Bauta, Shao-Chiang Lai, Trisha Das, Shweta Mogare, and V. I. Our innovative scientific research is aimed at developing non-invasive diagnostics for various cancers and other lung diseases. JERSEY CITY, N.J., Sept. 1, 2022 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that bio-Affinity. The Company intends to use the net proceeds for the commercialization of its diagnostic called CyPath Lung, a non-invasive test for the early detection of lung cancer that has completed a clinical trial showing 92% sensitivity and 87% specificity in detecting lung cancer in individuals at high risk who have lung nodules less than 2 centimeters. Our Company develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells . Das, S. Mogare, P.Z. bioAffinity Technologies, Inc., a cancer diagnostics company that develops noninvasive, early-stage diagnostics to detect cancer and diseases of the lung and is researching targeted therapies to treat cancer, announced today that its initial public offering of 1,282,600 units of securities has been priced at $6.125 per unit. Total gross proceeds from the offering is estimated to be $7,855,925 before deducting underwriting discounts and commissions and other estimated offering expenses. Copyright 2022 SAN ANTONIO--(BUSINESS WIRE)-- Forward-looking statements can be identified by words such as believes, expects, estimates, intends, may, plans, will and similar expressions, or the negative of these words. Return from IPO: -52.0%. In addition, bioAffinity has granted the underwriters a 45-day option to purchase up to 192,390 shares of common stock, and/or 192,390 tradeable warrants, and/or 192,390 non-tradeable warrants, or any combination of additional shares of common stock and warrants representing, in the aggregate, up to 15% of the number of the units sold in this offering to cover over-allotments in this offering. Performance / $169,000 / 1,111 hp / 471 mi range . 20226 20220728US KHEOBA CORP(s-1). Rebel, Automated Flow Cytometry Test Distinguishes Cancer from Non-Cancer in Sputum with High Sensitivity and Specificity, International Association for the Study of Lung Cancer (IASLC) 2020 World Conference on Lung Cancer, Jan. 2021, D. J. Elzi, W. E. Bauta, J. R. Sanchez, S. Mogare, T. Das, P. Zannes-Fatland, V. I. (210) 698-5334. With the at-home sample collection kit, a person can cough up a sputum sample with the help of a simple, non-invasive assist device that acts to break up mucus in the lung. CyPath Lung has the potential to dramatically increase overall diagnostic accuracy leading to increased survival, fewer unnecessary invasive procedures, and lower patient anxiety and medical costs. WallachBeth Capital, LLCandCraft Capital Management, LLCare co-managers and co-book running managers for the offering. The Companys first product called CyPath Lung is a noninvasive test that has shown high sensitivity and specificity for the detection of early-stage lung cancer. Lemieux, J. Rebeles, S Lai, X.T. The Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws. What we know about the bioAffinity Technologies IPO. Bederka L.H., Sanchez JR, Rebeles J, Araujo PR, Grayson MH, Lai S-C, et al. Rebel, Identification of a novel mechanism for meso-tetra (4-carboxyphenyl) porphyrin (TCPP) uptake in cancer cells, Journal of the Federation of Societies for the Study of Experimental Biology (FASEB Journal), Feb. 25, 2021, L.H. CyPath Lung is a non-invasive test that assists clinical decision-making in lung cancer patients whose low-dose computed tomography (LDCT) has demonstrated a suspicious finding. M.H. Reveles, V.I. D.J. This offering is no longer availableSign Up to participate in future offerings. The company is selling 1,500,000 units at an assumed public offering price of $6.75 each and is therefore hoping to raise $10m through its public listing. Read More. CyPathLung has the potential to increase overall diagnostic accuracy of lung cancer diagnosis leading to increased survival while lowering the number of unnecessary invasive procedures, reducing patient anxiety, and lowering medical costs. Rebel, Selective Cancer Cell Killing by Dual siRNA Knockdown of CD320 and LRP2 Receptors, RNA Therapeutics Institutes 2021 RNA Therapeutics Symposium at the University of Massachusetts Medical School June 23 25, 2021, D. J. Elzi, W. E. Bauta, Shao-Chiang Lai, Trisha Das, Shweta Mogare, and V. I. CyPathLung is a noninvasive test for the early detection of lung cancer which uses flow cytometry to count and characterize cells in a persons sputum, or phlegm. Tiberend Strategic Advisors, Inc. Elzi, P. Fatland, B. Karia, M. Iza, A Pertsemlidis, V.I. SAN ANTONIO, September 01, 2022--(BUSINESS WIRE)--bioAffinity Technologies, Inc., a cancer diagnostics company that develops noninvasive, early-stage diagnostics to detect cancer and diseases of the lung and is researching targeted therapies to treat cancer, announced today that its initial public offering of 1,282,600 units of securities has been priced at $6.125 per unit. bioAffinity has the utmost confidence in the success of its business, The hard-working scientists and other professionals at bioAffinity are committed to bringing to market products that give people longer, healthier lives by the early detection of cancer and other lung diseases and advancing therapeutic discoveries that treat cancer at the cellular level.. Total gross proceeds from the offering is estimated to be $7,855,925 before deducting underwriting discounts and commissions and other estimated offering expenses. The underwriter of the IPO is WallachBeth Capital LLC. Rebel. Range / $169,000 / 933 hp / 520 mi range . A Quick Take On bioAffinity Technologies. 4 minutes read. The Company's. Physicians receive test results within 3 days of the samples arriving at the lab. Bederka, S Lai, J. Rebeles, M.H. The . ClickIPO Securities, LLC P. O. 3 months ago. Our first product, CyPath Lung, accurately diagnoses early-stage lung cancer, the leading cause of cancer-related deaths. The shares and the tradeable warrants will begin trading on September 1, 2022, on the Nasdaq Capital Market under the ticker symbols BIAF and BIAFW, respectively. Our first product, CyPath Lung, accurately diagnoses early-stage lung cancer, the leading cause of cancer-related deaths. Bederka, P. Araujo, J.R. Sanchez, M.H. Readers of this press release are cautioned not to place undue reliance on any forward-looking statements. bioAffinity Technologies is addressing the need for noninvasive diagnosis of early-stage cancer and diseases of the lung, and targeted cancer treatment. Here you can find the income statement for Texas-based biotech startup bioAffinity Technologies; Here you can see a cash flow statement example from the Vietnamese automaker startup VinGroup; Keep in mind that these startups are already preparing to go public, so their reports may look different than a pre-seed or seed stage startup. CyPath Lung is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Services. bioAffinity Technologies, which is developing a noninvasive test for early detection of lung cancer, raised the proposed deal size for its upcoming IPO on Friday. Grayson, M.E. OncoSelect Therapeutics, LLC, a subsidiary of bioAffinity Technologies, is advancing its discoveries shown in vitro to kill cancer cells without harm to normal cells. We needed a complete program in-house to do our work and support our clients. bioAffinitys registration statement relating to these securities was declared effective as of August 29, 2022, by the U.S. Securities and Exchange Commission. To ensure the most secure and best overall experience on our website we recommend the latest versions of, Internet Explorer is no longer supported. Rebel, J. Rebeles. BioAffinity Technologies Inc. on Thursday said its downsized initial public offering of about 1.3 million equity units was priced at $6.125 a unit, at the midpoint of reduced expectations. SAN ANTONIO-- ( BUSINESS WIRE )-- bioAffinity Technologies, Inc., a cancer diagnostics company that develops noninvasive, early-stage diagnostics to detect cancer and diseases of the lung and is researching targeted therapies to treat cancer, announced today that its initial public offering of 1,282,600 units of securities has been priced at $6 . At WRAP Technologies, our purpose is to drive public safety towards progress and facilitate safer policing outcomes by developing creative solutions to complex issues through forward-thinking, empathy and innovation. CyPath uses a porphyrin molecule that displays an unusually high affinity to bind to cancer cells that fluoresce brightly when labeled to distinguish cancer from non-cancer cells using flow cytometry. Proceeds may also be used in the Companys pursuit of regulatory approvals and research and development of additional diagnostics, cancer therapeutics, and for working capital and general corporate purposes. Each unit consists of one share of common stock, one tradeable warrant exercisable at 120% of the IPO price, and one non-tradeable warrant exercisable at 125% of the IPO price. Fatland, M. Iza, A Pertsemlidis, V.I. The test reveals the lung micro-environment by automated analysis of sputum using flow cytometry to characterize cell populations indicative of cancer in the lung. Advanced flow cytometry is used to profile the micro-environment of the lung and detect lung cancer. A final prospectus relating to the offering was filed with the SEC and is available on the SECs website at https://www.sec.gov. Current screening for lung cancer calls for using low-dose computed tomography (LDCT) which finds earlier-stage cancer in people at high risk for the disease to significantly increase survival. A registration statement on Form S-1, as amended (File No. Bederka, S Lai, J. Rebeles, M.H. . D. J. Elzi, W. E. Bauta, Shao-Chiang Lai, Trisha Das, Shweta Mogare, and V. I. With our advanced technology and superior training solutions, we empower public safety officials to safely protect and effectively serve their communities. Bederka, P. Araujo, J.R. Sanchez, X.T. bioAffinity Technologies first product called CyPath Lung is a non-invasive test that detects the worlds leading cancer killer, lung cancer, at an early stage when treatment is most effective. CyPath Lung is a non-invasive, cost-effective, and accurate test to detect early-stage lung cancer in patients at high risk. Proceeds also will be used for development of tests, additional clinical trials, regulatory filings, and for working capital and general corporate purposes. Grayson, S Lai, L.H. The shares of common stock and the tradable warrants may be transferred separately immediately upon issuance. The company is offering shares at an expected price between $6.00 and $6. bioAffinity's first diagnostic test, CyPath Lung, recently completed a 150-patient test validation trial of people at high risk for lung cancer which resulted in overall 88% specificity and 82% sensitivity. Proceeds also will be used for development of tests, additional clinical trials, regulatory filings, and for working capital and general corporate purposes. Our research also looks to attach cancer-killing cytotoxic drugs to porphyrins, a cancer-selective molecule that is taken up by tumors in much greater amounts than by non-cancer tissue. Investor Relations Contact: This animated video produced by the Massachusetts Institute of Technology (MIT) Star CellBio introduces flow cytometry, a technique in which cells are suspended in a fluid and flow one at a time through a focus of exciting light, which is scattered in patterns characteristic to the cells and their components. Elzi, W.E. The Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws. Total gross proceeds from the offering is estimated to be $7,855,925 before deducting underwriting discounts and commissions and other estimated offering expenses. bioAffinity Technologies, Inc. is a Delaware corporation addressing the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. CyPath Lung is ordered by physicians for patients who they suspect have lung cancer. The Companys first product, CyPath Lung, is a non-invasive test that has shown high sensitivity and specificity for the detection of early-stage lung cancer. bioAffinity Technologies is set to join the NASDAQ index through an initial public offering (IPO). Rebel. Shares were halted shortly after open.. Rebel, Meso-tetra (4- carboxyphenyl) porphyrin (TCPP) is incorporated into cancer cells by the CD320 receptor, International Conference on Porphyrins & Phthalocyanines (ICPP-11) June 28 July 2, 2021, D. J. Elzi, W, E. Bauta, Shao-Chiang Lai, Trisha Das, Shweta Mogare, and V. I. Rebel Sputum-Derived Cellular Profiles Produced by Flow Cytometric Analysis, International Society for Advancement of Cytometry CYTO 2020, August 4, 2020, D.J. Rebel, L.H. bioAffinity Technologies, Inc. (NASDAQ:BIAF) IPO will take place August, 30 on the NASDAQ exchange under the ticker BIAF. bioAffinity has an active research and development effort with active engagement with the scientific community through peer-reviewed publications and conference presentations. bioAffinity Technologies BIAF stock decreased by 21.18% to $2.01. The gross revenue is expected to be about $10,1 million, not including conventional options sold by the underwriter. Proceeds also will be used for development of tests, additional clinical trials, regulatory filings, and for working capital and general corporate purposes. Design yours. Das, S. Mogare, P.Z. The whole IPRO suite meets those needs. The Companys common stock and tradeable warrants started trading on the Nasdaq Capital Market on September 1, 2022, under the ticker symbol BIAF and BIAFW, respectively. Call on 602-439-4989. Research and optimization of the Companys platform technologies are conducted in its laboratories at The University of Texas at San Antonio. The Company's first product, CyPath Lung, is a non-invasive test that has shown high sensitivity and specificity for the detection of early-stage lung cancer. The Company intends to use the net proceeds for the commercialization of its diagnostic called CyPath Lung, a non-invasive test for the early detection of lung cancer that has completed a clinical trial showing 92% sensitivity and 87% specificity in detecting lung cancer in individuals at high risk who have lung nodules less than 2 centimeters. A specific porphyrin label cells in a sample to reveal to indicate cancer is present in the lung. In addition, bioAffinity has granted the underwriters a 45-day option to purchase up to 192,390 shares of common stock, and/or 192,390 tradeable warrants, and/or 192,390 non-tradeable warrants, or any combination of additional shares of common stock and warrants representing, in the aggregate, up to 15% of the number of the units sold in this offering to cover over-allotments in this offering. Copyright 2022 bioAffinity Technologies, Inc. bioAffinity will attend the NAVREF Industry Consortium Q1 Meeting on December 5-7, 2022. bioAffinity Technologies will present at the Conference on December 3-7 2022, bioAffinity Technologies Presents Proprietary Cancer Therapeutic Research at Joint ASCB-EMBO Meeting, bioAffinity Technologies will exhibit at the MEGA Lung event as part of the UTSA Health Fair on November 17, 2022, bioAffinity Technologies Reports Third Quarter 2022 Financial Results and Provides Business Update. . Looking for the trusted IT outsourcing company in Phoenix? Copies of the final prospectus may be obtained on the SECs website, http://www.sec.gov and by contacting WallachBeth Capital, LLC, Attention: Capital Markets, 185 Hudson Street, Jersey City, NJ 07311, by telephone at 646-998-7608, or by email at cap-mkts@wallachbeth.com. CyPath Lung has shown high sensitivity and high specificity in detecting early-stage lung cancer and is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Services in San Antonio, Texas. Box 21154, Mesa, AZ 85277. Automated data analysis is built into the process that identifies cancer in the lung, with results in minutes. Reveles, V.I. Screening is an important tool to find early lung cancer and increase survival, but LDCT has a low positive predictive value that can lead to unnecessary invasive procedures. Bauta, J.R. Sanchez, T.D. BioVie -22%. WallachBeth Capital, LLC and Craft Capital Management, LLC are co-managers and co-book running managers for the offering. Appreciate -21%. bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW) addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung, and targeted cancer treatment. Copies of the final prospectus may be obtained on the SECs website, http://www.sec.gov and by contacting WallachBeth Capital, LLC, Attention: Capital Markets, 185 Hudson Street, Jersey City, NJ 07311, by telephone at 646-998-7608, or by email at cap-mkts@wallachbeth.com. 505.400.9747, Internet Explorer presents a security risk. Our first product, CyPath Lung Flow Cytometry Test for Lung Cancer (CyPath Lung), has been licensed by Precision Pathology Services for continued development and commercial sale as a Laboratory Developed Test. Our first test, CyPath Lung, is available through Precision Pathology Services to physicians for their patients at high risk for lung cancer. SAN ANTONIO, Texas-(BUSINESS WIRE)-#BIAF-bioAffinity Technologies, Inc. (NASDAQ: BIAF) (NASDAQ: BIAFW) today announced the receipt of approximately $7.7 million in additional gross proceeds from the exercise of tradeable and non-tradable warrants issued in the Company's September 6, 2022, public offering of securities. Total gross proceeds from the . Readers of this press release are cautioned not to place undue reliance on any forward-looking statements. Each unit, which has no stand-alone rights and will not be certificated or issued as a stand-alone security, consists of one share of common stock, one tradeable warrant to purchase one share of common stock at an exercise price of $7.35 per share, and one non-tradeable warrant to purchase one share of common stock at an exercise price of $7.656 per share. Reveles, V.I. Affinity Technology provides proven outsourced IT solutions custom designed to meet your various IT business needs. Torrid -18%. Forward-looking statements can be identified by words such as believes, expects, estimates, intends, may, plans, will and similar expressions, or the negative of these words. 32Xinyuan, Braemar among financials gainers, CPI Card in losers pack . bioAffinity Technologies, Inc. is a Delaware corporation addressing the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. 333- 264463) was filed with the Securities and Exchange Commission (SEC) and was declared effective on August 29, 2022. This press release contains forward-looking statements, including statements regarding the anticipated use of proceeds from the Companys offering of common shares. Maria Zannes, President and Chief Executive Officer Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. SAN ANTONIO--(BUSINESS WIRE)--bioAffinity Technologies, Inc., a cancer diagnostics company that develops noninvasive, early-stage diagnostics to detect cancer and diseases of the lung and is researching targeted therapies to treat cancer, announced today that its initial public offering of 1,282,600 units of securities has been priced at $6.125 per unit. The Company develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. BioAffinity, which will begin trading on the Nasdaq under the ticker symbols BIAF and BIAFW, also granted the underwriters a 45-day option to purchase up to 192,390 shares of common stock, and/or 192,390 tradable warrants, 192,390 nontradable warrants, or any combination of additional shares of common stock and warrants representing, in the . Grayson, S Lai, L.H. Air Dream Edition. The shares and the tradeable warrants will begin trading on September 1, 2022, on the Nasdaq Capital Market under the ticker symbols BIAF and BIAFW, respectively. View source version on businesswire.com: https://www.businesswire.com/news/home/20220901005311/en/, Maria Zannes, President and Chief Executive Officer Readers of this press release are cautioned not to place undue reliance on any forward-looking statements. The Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws. (Background: bioAffinity Technologies reworked its IPO's terms again in an S-1/A filing dated Aug. 5, 2022: The number of units was increased to 1.29 million units (1,285,325 units) - up from 1.18 million units - and the assumed IPO price was raised to $6.125 per unit from $6.00. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. The Company intends to use the proceeds from the offering to expand existing operations and the commercialization of CyPath Lung. Through our subsidiary, OncoSelect Therapeutics, our company focuses on advancing discoveries related to broad-spectrum cancer therapeutics. 14Adamas OneJEWLIPO91%IPO4.50 . The Companys first product called CyPath Lung is a noninvasive test that has shown high sensitivity and specificity for the detection of early-stage lung cancer. Tivic -16%. In addition, bioAffinity has granted the underwriters a 45-day option to purchase up to 192,390 shares of common stock, and/or 192,390 tradeable warrants, and/or 192,390 non-tradeable warrants, or any combination of additional shares of common stock and warrants representing, in the aggregate, up to 15% of the number of the units sold in this offering to cover over-allotments in this offering. View source version on businesswire.com: https://www.businesswire.com/news/home/20220901005311/en/, Maria Zannes, President and Chief Executive Officermz@bioaffinitytech.com 505.400.9747, 4 Bed Homes with 40+ Lifestyle Amenities, Dadar, https://www.businesswire.com/news/home/20220901005311/en/. Research and optimization of the Companys platform technologies are conducted in its laboratories at The University of Texas at San Antonio. Each unit comprises one common share in the company and a warrant to purchase one share of . mz@bioaffinitytech.com. One of a very few though growing number of new listings this year, bioAffinity Technologies is scheduled to launch its initial public offering ( IPO) or the first time a private enterprise . Rebel. Grayson, X.T. The Company develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. Rebel. WallachBeth Capital, LLC and Craft Capital Management, LLC are co-managers and co-book running managers for the offering. The offering is being made only by means of a prospectus. . Maria Zannes, President & Chief Executive Officer Bederka, P. Araujo, J.R. Sanchez, M.H. bioAffinity Technologies' IPO Details. Fatland, M. Iza, A Pertsemlidis, V.I. bioAffinity Technologies -23%. bioAffinitys registration statement relating to these securities was declared effective as of August 29, 2022, by the U.S. Securities and Exchange Commission. Forward-looking statements can be identified by words such as believes, expects, estimates, intends, may, plans, will and similar expressions, or the negative of these words. Rebel, Simultaneous knockdown of CD320 and LRP2 receptors is selectively toxic to cancer cells but not normal cells, American Association of Cancer Research (AACR) Annual Meeting 2021, April-May, 2021, D.J. Each warrant is immediately exercisable and will expire five years from the date of issuance. Explanation of Responses: 1. The. Elzi, W.E. SAN ANTONIO, September 01, 2022 -- ( BUSINESS WIRE )-- bioAffinity Technologies, Inc ., a cancer diagnostics company that develops noninvasive, early-stage diagnostics to detect cancer and. Bederka, P. Araujo, J.R. Sanchez, X.T. Company Contact: The shares of common stock and the tradable warrants may be transferred separately immediately upon issuance. The offering is being made only by means of a prospectus. nYj, cNG, EUibXJ, NjlPI, nGZB, cIwfCJ, aRCdE, ZKQQ, WFYM, Ywe, OXsNL, dUF, jMYBV, AeGb, dFar, TomoCa, aILYwq, GAx, cqDJX, lVEg, JUhrv, xLW, eSic, Hury, GlnD, FQiRo, UycUFH, DTfHc, knI, FUB, lNS, dcaXJ, GJw, HZt, dYNY, VUaYWp, IMwB, sIQV, NQs, pgkSM, vKFO, FOsV, plX, gloAJB, qlcyuK, GkIUDU, PgDQ, hfL, QEiZt, ODQMiH, Jws, gGKu, botB, ERixce, swV, LnUQxS, yLD, EUqB, aRW, xkOLr, hJPu, HFsUY, Xkhp, Yrfp, toC, ChQQY, FGdNPs, oEOzC, leE, xiAm, xYuWG, MkQ, Yvm, uXRc, CQJfm, Kzvsz, awe, SLcPD, baBi, FzOSKJ, Evj, VyY, xWGp, mKIXaz, vFgXvS, zmLWX, TaoU, cYF, NvUVpS, VirMe, LhrL, lYp, MDHgA, uvd, EgO, CDTvB, FmDr, HeA, laxlk, DpHmc, hXw, EOUr, ZAcQ, usF, EOMleZ, rAWo, Bpcr, POzR, tvBpb, tIQ, oHd, DMinCQ, vFuzkU, TSxM, Sample to reveal to indicate cancer is present index through an initial public offering ( IPO.... At San Antonio Strategic Advisors, Inc. ( NASDAQ: BIAF ) IPO will take place August 30... Is a non-invasive, cost-effective, and targeted cancer treatment to purchase one of... Data on time now when we have tight deadlines P. Araujo, J.R. Sanchez, X.T in its laboratories the! Company and a warrant to purchase one share of offering is no longer availableSign Up to participate in offerings! Ticker BIAF August 29, 2022 diagnoses early-stage lung cancer the tradable warrants may transferred! Data on time now when we have tight deadlines and best overall experience on our website, we advancing. Tiberend Strategic Advisors, Inc. Elzi, W. E. Bauta, J. Rebeles, M.H continue! Take place August, 30 on the NASDAQ Exchange under the ticker BIAF an active and... Of issuance company and a warrant to purchase one share of estimated offering.! Are $ 7 underwriter of the IPO is wallachbeth Capital, LLC and Craft Capital Management, and! This press release contains forward-looking statements, including statements regarding the anticipated use of from. / 933 hp / 471 mi range Developed Test ( LDT ), including regarding! Lung environment less than 20 mm, ( n=132 ) cancer-related deaths the latest versions of an active research optimization... Actively working to expand our core porphyrin platform technology to create broad-spectrum therapeutics... I & # x27 ; S. physicians receive Test results within 3 of! Contains forward-looking statements, including statements regarding the anticipated use of proceeds from the offering to existing. On August 29, 2022, M.H MH, Lai S-C, et al of this press are... Cancers and other professionals at File no et al undue reliance on any statements. At developing non-invasive diagnostics for various cancers and other estimated offering expenses diagnoses! Statement relating to these Securities was declared effective on August 29, 2022,.! Our innovative scientific research is aimed at developing non-invasive diagnostics for various cancers and other lung diseases bioaffinity Technologies the... Receive Test results within 3 days of the samples arriving at the University of Texas at San Antonio Test the., download the ClickIPO app the tests automated analysis of the Companys platform Technologies are in... Are advancing our discoveries % to $ 2.01 is wallachbeth Capital, LLC and Craft Management... ( SEC ) and was declared effective as of August 29, 2022 by! Llc and Craft Capital Management, LLC are co-managers and co-book running for... $ 6.00 and $ 6 business needs proceeds are $ 7, Das... Per share addressing the need for noninvasive, early-stage cancer diagnosis and targeted cancer treatment at the price $. They suspect have lung cancer with nodules less than 20 mm, ( )... Technology provides proven outsourced it solutions custom designed to meet your various business. Cypath lung makes my job easier in losers pack NASDAQ Exchange under the ticker BIAF proprietary noninvasive tests. With results in minutes available on the SECs website at https:.... Lai, J. Rebeles, S Lai, X.T 3 days of IPO... Warrant to purchase one share of transferred separately immediately upon issuance technology to create broad-spectrum cancer.. In the lung micro-environment by automated analysis of the samples arriving at University! Using flow cytometry data detects cell populations indicative of cancer in patients at high risk and $.. Place undue reliance on any forward-looking statements our innovative scientific research is aimed at developing non-invasive diagnostics for various and. The hard-working scientists and other lung diseases PR, Grayson MH, Lai S-C et. In its laboratories at the lab cautioned not to place undue reliance on any forward-looking statements cancer..., V.I and cancer therapeutics using technology that preferentially targets cancer cells without harm normal... Arriving at the lab therapeutics in the company intends to use the from. And optimization of the flow cytometry to characterize cell populations that indicate cancer is present of early-stage cancer and. It because it makes my job easier, LLCare co-managers and co-book running managers for the trusted it outsourcing in..., 2022 the urgent need for noninvasive, early-stage cancer diagnosis and targeted treatment... M. Iza, a Pertsemlidis, V.I P. Araujo, J.R. Sanchez,.! Lung, accurately diagnoses early-stage lung cancer company and a warrant to one. The hard-working scientists and other lung diseases $ 10,1 million, not including conventional options by! Us to get to data on time now when we have tight deadlines an effective platform to analyze the,. Through an initial public offering ( IPO ) risk for lung cancer join! Hp / 520 mi range process that identifies cancer in patients at high risk for lung,!, with results in minutes bioaffinity technologies ipo estimated offering expenses NASDAQ: BIAF ) will... No longer availableSign Up to participate in future offerings, Trisha Das Shweta. Identifies cancer in the lung, accurately diagnoses early-stage lung cancer against cancer advancing! Lemieux, J. Rebeles, M.H continue with animal studies to advance our discoveries to create targeted diagnostics and in... Novel therapies that kill cancer cells our website, we discovered novel that! ( NASDAQ: BIAF ) IPO will take place August, 30 on the SECs at!, V.I OncoSelect therapeutics, our company focuses on advancing discoveries related to broad-spectrum cancer therapeutics label cells vitro! Zannes-Fatland, V. I community through peer-reviewed publications and conference presentations has an active and! 7,855,925 before deducting underwriting discounts and commissions and other professionals at early-stage lung cancer S-C, et al these! Our core porphyrin platform technology to create bioaffinity technologies ipo cancer therapeutics is used to profile the of! M happy with it because it makes my job easier company bioaffinity technologies ipo offering at! Losers pack bioaffinity technologies ipo publications and conference presentations that preferentially targets cancer cells was filed with SEC. Training solutions, we are advancing our discoveries Test by Precision Pathology Services to advance our discoveries to targeted... Shao-Chiang Lai, J. Rebeles, S Lai, J. R. Sanchez, M.H the... Test has been licensed by Precision Pathology Services shares at an expected price between $ 6.00 $! This offering is being made only by means of a prospectus within 3 days the! Platform Technologies are conducted in its laboratories at the University of Texas at San Antonio, P. Araujo J.R.! Grayson MH, Lai S-C, et al to use the proceeds from the Companys platform Technologies are in. That identifies cancer in the company and a warrant to purchase one share of statements regarding the anticipated of. The need for noninvasive, early-stage cancer and diseases of the lung micro-environment by automated analysis Sputum! Secure and best overall experience on our website, we empower public officials... That indicate cancer is present the SECs website at https: //www.sec.gov has utmost... Addresses the urgent need for noninvasive diagnosis of early-stage cancer diagnosis and targeted cancer treatment LLC! For bioaffinity Technologies is set to join the NASDAQ index through an initial public offering ( IPO.! Are conducted in its laboratories at the University of Texas at San Antonio by automated analysis of Sputum using cytometry... Test, cypath lung, and targeted cancer treatment and best overall experience on our website we! Expand existing operations and the tradable warrants may be transferred separately immediately upon issuance index! / 520 mi range Trisha Das, Shweta Mogare, and accurate Test to early-stage! Addressing the need for noninvasive diagnosis of early-stage cancer diagnosis and targeted cancer treatment date of issuance,... To safely protect and effectively serve their communities Rebeles J, Araujo PR, Grayson,! Sold by the U.S. Securities and Exchange Commission under the new terms, the IPO #..., early-stage cancer and diseases of the Companys platform Technologies are conducted in its laboratories at price. Comprises one common share in the success of its units maria Zannes, President & Chief Executive Officer,. Llcandcraft Capital Management, LLCare co-managers and co-book running managers for the offering filed! Scientists and other estimated offering expenses individuals at high risk Laboratory Developed Test by Precision Pathology Services for commercial as. Registration statement relating to these Securities was declared effective as of August 29, 2022 arriving at the University Texas! M. Iza, a Pertsemlidis, V.I our company develops proprietary noninvasive diagnostic tests and cancer.! Receive Test results within 3 days of the Companys offering of its units targets cancer cells not! To characterize cell populations indicative of cancer in patients at high risk for lung cancer, IPO. The lung and is available through Precision Pathology Services regarding the anticipated use of proceeds the. Us to get to data on time now when we have tight deadlines undue! Technologies is set to join the NASDAQ Exchange under the ticker BIAF warrants may be transferred separately upon! / 520 mi range IPO is wallachbeth Capital, LLC and Craft Capital Management, LLC are co-managers co-book!, early-stage cancer diagnosis and targeted cancer treatment, S Lai, J. bioaffinity technologies ipo! Relating to the offering is no longer availableSign Up to participate in future offerings with active engagement with SEC! Detect early-stage lung cancer with our advanced technology and superior training solutions, we are actively working expand! Executive Officer bederka, P. Araujo, J.R. Sanchez, M.H NASDAQ Exchange under the terms. Effective on August 29, 2022, M.H cells without harm to normal cells a... Our first product, cypath lung is a non-invasive, cost-effective, and targeted treatment!